Dr. Edgar Ribi, who pioneered the field of proprietary adjuvants, tried unsuccessfully to popularize the term "theraccine" for therapeutic vaccines so as not to confuse with prophylaxis. Most unfortunate IMO that both Dr. Ribi's vision and guidance were lost when a plane he was piloting to a scientific convention crashed. His company took longer to die in the hands of incompetents but the purchase on the cheap of Ribi Immonochem Research was about all that CRXL had left when that fine outfit died from overpromotion and lack of good science.
Nabi Biopharmaceuticals Presents Data Showing Patients Treated with Altastaph Were Relieved of Fever and Bacteremia Sooner than the Placebo Group
Friday October 7, 6:30 pm ET
ROCKVILLE, Md., Oct. 7 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals (Nasdaq: NABI - News) announced today, for the first time, data showing that patients treated with Altastaph(TM) [Staphylococcus aureus Immune Globulin Intravenous (Human)] had a shorter duration of bacteremia (bloodstream infections) and fever versus the placebo group. As previously reported, the treated group also left the hospital sooner...
Dr. Rupp's presentation focused on the results of the Altastaph U.S. Phase I/II clinical trial in treating adult in-hospital patients with persistent S. aureus bacteremia...
Altastaph is an investigational human antibody-based product containing high levels of antibodies to capsular polysaccharides (protective outer sugar coatings on S. aureus bacteria) from S. aureus types 5 and 8, which together account for approximately 85 percent of all S. aureus infections. Altastaph is produced by immunizing healthy volunteers with StaphVAX® (Staphylococcus aureus Polysaccharide Conjugate Vaccine), Nabi Biopharmaceuticals' vaccine being investigated for the prevention of S. aureus infections.
Market Data 
Markets 
AI
